CD274 and neoplasm: The 5-year CheckMate227 Part 1 results indicated that ipilimumab and nivolumab improved overall survival (OS) compared to chemotherapy in patients with metastatic NSCLC, particularly those without PD-L1 expression in the tumor [9].